AADI Aadi Bioscience Inc Forward P/S Multiple

Aadi Bioscience is led by experienced pharmaceutical market experts who ensure the transparency of Fyarro drug metrics. Slow sales growth coupled with high R&D expenses are constraining profits; therefore, the company's modeled P/S helps assess the expansion stage, where the 2.00 level captures fresh values. Business flexibility is maintained through the complete outsourcing of production and clinical trials to third-party organizations.

AADI (Aadi Bioscience, Inc.) Price to Expected Revenue Ratio history from 07/04/2022 to 03/19/2025

aadibio.com - analytical breakdowns and key metrics (AADI)

- current price and projected stock value:

Stock Price Aadi Bioscience, Inc.|AADI - Analyst Target Range

- market capitalization data:

Market Capitalization AADI|AADI - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Aadi Bioscience|AADI - Total Net Assets|Market Capitalization to Book Value Ratio aadibio.com|AADI - Company Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

AADI - Company Net Income|Expected Profit Aadi Bioscience|AADI - Company Value to Net Income|Forward P/E Multiple Aadi Bioscience, Inc.|AADI - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AADI|AADI - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Aadi Bioscience|AADI - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth aadibio.com|AADI - Earnings growth in current year|Earnings growth forecast for next year Aadi Bioscience

- issuer revenue and sales details:

AADI - Revenue and Sales Volume|Projected Sales Volume Aadi Bioscience, Inc.|AADI - Market Cap to Revenue Ratio|Forward P/S Multiple AADI

Summary company analysis:Aadi Bio (AADI)

For Aadi Bioscience (AADI), which focuses on clinical trials of targeted oncology drugs without an M&A strategy, the forward price-to-sales chart serves as an indicator of market expectations for future sales. This metric is calculated as the ratio of current market capitalization to projected revenue, allowing investors to assess the extent of the technological potential priced in and the risks of overpaying for innovation given the high dependency on successful trial outcomes.

Competing companies